Provided herein, inter alia, are methods for detecting brain structure modulations associated with impaired inhibitory control disorders (ICD). The methods are useful for treating of a variety of neurological and psychiatric conditions, and can include neurostimulation to specific regions of the brain.

A method comprises generating, by an implantable stimulator, stimulation sessions at a duty cycle that is less than 0.05 and applying, by the implantable stimulator in accordance with the duty cycle, the stimulation sessions to a patient. The duty cycle is a ratio of T3 to T4. Each stimulation session included in the stimulation sessions has a duration of T3 minutes and occurs at a rate of once every T4 minutes. The implantable stimulator is powered by a primary battery located within the implantable stimulator and having an internal impedance greater than 5 ohms.

Devices and methods for manipulating devices such as micro-scale devices are provided. The devices can include a tether of various materials surrounded by a stiff body. The tether interfaces with microscale devices to draw them against the stiff body, holding the microscale devices in a locked position for insertion into or extraction out of tissue. The tensional hook and stiff body are configurable in a multitude of positions and geometries to provide increased engagement. Such configurations allow for a range of implantation and extraction surgical procedures for the device within research and clinical settings.

Methods for treating a subject for a parasympathetic bias mediated condition are provided. Aspects of the methods include modulating at least a portion of the subject's autonomic nervous system to increase the sympathetic/parasympathetic activity ratio in a manner effective to treat the subject for the parasympathetic bias mediated condition. In some instances, the subject is known to have parasympathetic bias. Also provided are devices that find use in practicing various embodiments of the methods.

Systems and methods for spinal cord electrode placement and spinal cord stimulation their use for treatment of conditions such as obesity are disclosed. In one example approach, during placement of a spinal cord stimulating electrode in a target region of the brain of a patient, a temperature of brown adipose tissue may be monitored, e.g., via a supraclavicular temperature sensor implanted in the patient, and used to identify an optimal location of electrode stimulation which causes an increase in BAT temperature. Additionally, BAT temperature measurements may be used to provide regulated closed-loop control to increase efficiency of spinal cord stimulation while reducing energy consumption of the pulse generator. Further, core temperature measurements may be obtained from the electrode in the spinal cord and used to adjust spinal cord stimulation.

The present invention concerns an optoelectronic stimulating device for use in a medical treatment involving delivering an electrical current to an electrically excitable tissue (Z.sub.bio) by means of two electrodes (3n, 3p) electrically coupled to said tissue, said optoelectronic stimulating device comprising: (a) a source (4) of electrical impulses, which is electrically connected to (b) a source of light emission (2), in optical communication with (c) a photovoltaic cell (1) electrically connected to two electrodes (3n, 3p) for establishing two electrical contacts with said tissue and thus forming an electrical stimulating circuit fed by the photovoltaic cell (1) which is energized by the radiation of the source of light emission (2).

A method for treating conditions associated with impaired glucose control, involving inhibition of signalling by the greater splanchnic nerve leads to a significant improvement in oral glucose tolerance.

The disclosed electrical stimulation system generates interventions to assist patients in complying with a diet. The wearable device includes a microprocessor, electrical stimulator and at least one electrode configured to deliver electrical stimulation to the epidermis, through a range of 0.1 mm to 10 mm or a range of 0.1 mm to 20 mm of the dermis, of a T2 dermatome to a T12 dermatome or meridian of the patient, a C5 to a T1 dermatome across the hand and/or arm, and/or the upper chest regions. The device is adapted to provide electrical stimulation as per stimulation protocols and to communicate wirelessly with a companion control device configured to monitor and record appetite patterns of the patient and generate interventions. The control device is also configured to monitor, record, and modify stimulation parameters of the stimulation protocols.

The present application relates to a new stimulation design which can be utilized to treat neurological conditions. The stimulation system produces a burst mode stimulation which alters the neuronal activity of the predetermined site, thereby treating the neurological condition or disorder. The burst stimulus comprises a plurality of groups of spike pulses having a maximum inter-spike interval of 100 milliseconds. The burst stimulus is separated by a substantially quiescent period of time between the plurality of groups of spike pulses. This inter-group interval may comprise a minimum of 5 seconds.

An oral device for use with a person in which at least one non-toxic gas pulse is delivered to a predetermined location in the mouth via a device conduit. The oral device may be provided as a kit with at least one device for measuring the subject's responses and representing them as feedback to the subject/clinician. A method of creating a gas bolus pulse train, delivering it to a predetermined mouth area, and monitoring the subject's responses to it, is also shown. The oral device and method may be used as a diagnostic tool, or a therapeutic tool, in swallowing or speech rehabilitation of children and adults who have swallowing, speech, salivary, and/or oral sensorimotor impairments.